Oxytocin

Status FDA-approved (generic, Pitocin) for IV/IM obstetric use; intranasal use for social/psychiatric indications is not approvedBest evidence E3Sources checked 2026-09-18

Oxytocin is FDA-approved as an IV/IM obstetric drug (Pitocin) for labor and postpartum bleeding, a completely different use from the unapproved intranasal form studied for social cognition and psychiatric conditions. A 2026 meta-analysis of 42 RCTs found an overall effect close to zero for that intranasal use.

Identity

Sequence: Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2 (9-amino-acid cyclic peptide with a disulfide bridge)

What it is

Oxytocin is a naturally occurring 9-amino-acid human hormone, released by the posterior pituitary, with well-established roles in labor, milk letdown, and social/pair-bonding behavior in animal models. A synthetic version has been an FDA-approved drug for decades, sold generically and under the brand name Pitocin, given intravenously or intramuscularly to induce or augment labor and to control postpartum bleeding.

A separate, much newer research and commercial story concerns intranasal oxytocin, studied for its effects on social cognition, trust, anxiety, and psychiatric conditions including autism spectrum disorder and schizophrenia. This intranasal use has no FDA approval, and it should not be confused with the approved obstetric drug: different route, different population, different evidence base entirely.

The approved use versus the circulating one

The obstetric use is old, well-studied, and dosed precisely by IV infusion titrated to uterine response, under labor and delivery monitoring.

The intranasal, psychiatric/social-cognition use is a different story. A 2026 meta-analysis pooling 42 double-blind randomized controlled trials of intranasal oxytocin versus placebo across autism spectrum disorder, schizophrenia-spectrum disorders, substance use disorders and other mental disorders (total n=1,922) found a small, non-significant overall effect (g=0.17, 95% CI -0.05 to 0.38) with substantial heterogeneity between trials; removing two outlier studies eliminated the heterogeneity and reduced the pooled effect further (g=0.05, 95% CI -0.03 to 0.12), essentially no effect. A significant, small benefit emerged only in the schizophrenia-spectrum subgroup (g=0.12).

Specifically for autism, an earlier systematic review and meta-analysis of 10 randomized controlled trials in adults found no significant efficacy of intranasal oxytocin for anxiety, repetitive behavior, social function or overall severity.

What is not established

Any general benefit of intranasal oxytocin for social cognition, bonding, anxiety or mood in a healthy person taking it outside a clinical trial. The largest recent meta-analysis pooling trials across several psychiatric conditions found an effect close to zero once outlier studies were removed.

Optimal dose, frequency or duration for any of the unapproved intranasal uses; the 2026 meta-analysis specifically found no significant moderation by dose or number of administrations across the pooled trials, meaning the field has not established a dose-response relationship even within its own trial data.

What is not known

Any general benefit of intranasal oxytocin for social cognition, bonding, anxiety or mood in a healthy person outside a clinical trial. The largest recent pooled meta-analysis found an effect close to zero.

Optimal dose, frequency or duration for any unapproved intranasal use; pooled trial data found no significant dose-response relationship.

Doses used in published research

No published study has administered this compound to a human being, so no dose appears in the literature and none has been established.

Amounts above record what a named source reported administering in a study. They are not a recommendation, not a protocol, and not instructions.

Converting a vial and a syringe into a draw volume is a separate, mechanical question from what amount to use. The reconstitution calculator does that arithmetic for peptide, HCG, and HGH vials.

What circulates E5

Figures reported online. Not dosing, not verified, not endorsed.
Reported use	Route	Amount reported	Frequency	Reported length
Social bonding/anxiety, general	Intranasal	20 to 40 IU per dose	Once or twice daily	Ongoing

Circulating intranasal oxytocin material describes 20 to 40 IU per dose, once or twice daily, a range consistent with what most of the pooled clinical trials actually used. The gap here is not dose, it is outcome: the largest recent meta-analysis of that same dosing approach, pooled across 42 trials in several psychiatric conditions, found an overall effect indistinguishable from placebo once outlier studies were excluded. Matching the studied dose does not mean matching a studied benefit.

Recorded as an observation about what is published elsewhere. No figure here is a dose, a protocol, or a recommendation, and nothing in this section is evidence that any amount is safe or effective.